References
- Ding Y, Sun L, Wang Y, Zhang J, Chen Y. Efficacy of ICS versus non-ICS combination therapy in COPD: a meta-analysis of randomised controlled trials. Int J Chron Obstruct Pulmon Dis. 2022;17:1051–1067. doi:10.2147/COPD.S347588
- Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;2014(12). doi:10.1002/14651858.CD010115
- Mammen MJ, Lloyd DR, Kumar S, et al. Triple therapy versus dual or monotherapy with long-acting bronchodilators for chronic obstructive pulmonary disease. A systematic review and meta-analysis. Ann Am Thorac Soc. 2020;17(10):1308–1318. doi:10.1513/AnnalsATS.202001-023OC
- Koarai A, Yamada M, Ichikawa T, Fujino N, Kawayama T, Sugiura H. Triple versus LAMA/LABA combination therapy for Japanese patients with COPD: a systematic review and meta-analysis. Respir Investig. 2022;60:90–98. doi:10.1016/j.resinv.2021.04.007
- Stanbrook MB; ACP Journal Club. Review: in COPD, fluticasone or budesonide increases serious pneumonia but not mortality. Ann Intern Med. 2014;161:JC8. doi:10.7326/0003-4819-161-4-201408190-02008
- Teramoto S. The current definition, epidemiology, animal models and a novel therapeutic strategy for aspiration pneumonia. Respir Investig. 2022;60(1):45–55. doi:10.1016/j.resinv.2021.09.012